Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression.
Association between IRF5 polymorphisms and autoimmune diseases: a meta-analysis.
Microglia as a critical player in both developmental and late-life CNS pathologies.
Distilling the essence of appraisal: a mixed methods study of people with multiple sclerosis.
Cytomegalovirus and multiple sclerosis risk.
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis.
In vivo Positron Emission Tomography Imaging Demonstrates Diminished Microglial Activation after Fingolimod Treatment in an Animal Model of Multiple Sclerosis.
Fingolimod (Gilenya) may improve the chances of conception in women with multiple sclerosis (MS) associated with secondary infertlity.
Burden of risk variants correlates with phenotype of multiple sclerosis.
HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
Tysabri Review Launched in Europe
Alterations of juxtaparanodal domains in two rodent models of CNS demyelination.
Quality of life in patients with multiple sclerosis.
The fumaric acid ester BG-12: a new option in MS therapy.
Estimating time-varying effects for overdispersed recurrent events data with treatment switching.
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Alternative Approaches: A Systematic Review of Non-Pharmacological Treatments for Non-Spastic and Non-Trigeminal Pain in Patients with Multiple Sclerosis.
The need for a multiple sclerosis registry in the Gulf Region.
Allopregnanolone and neuroinflammation: a focus on multiple sclerosis.
Current and Future Therapies Targeting the Immune System in Multiple Sclerosis.
Functional outcomes associated with expiratory muscle strength training: Narrative review.
Ginger Extract Reduces the Expression of IL-17 and IL-23 in the Sera and Central Nervous System of EAE Mice.
Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids.
Pages
« first
‹ previous
…
396
397
398
399
400
401
402
403
404
…
next ›
last »